In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...

FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has secured a US notice of allowance for a continuation patent covering its ...

A Guildford-based developer of sexual health products, including erectile dysfunction treatment Eroxon, has reported strong trading in a new update.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...

Researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered compelling evidence that individuals with Down syndrome experience ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript February 3, 2026 Operator: Good day, everyone. And ...

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

But in a figurative sense – and at least one literal sense – Trump is right. Portland is constantly on fire. In the year following July 2024, Portland had 6,268 fire-related incidents – and 40% of the ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

She was absolutely, utterly exhausted. It was the morning of Christmas Eve, and her kids, almost 4 and 2, woke her up “way ...